Research and License agreements between National Cheng Kung University and Novo Nordisk A/S
Taipei, May 18 (CNA) A southern Taiwan-based National Cheng Kung University (NCKU) research team led by Ming-Shi Chang, NCKU professor of the Department of Biochemistry and Molecular Biology, has discovered an anti-interleukin-20 (anti-IL-20) antibody, a potential new anti-osteoporosis and anti-rheumatoid arthritis drug, and agrees to license selected intellectual property and transfer certain technology to Novo Nordisk A/S, a Danish-based pharmaceutical company for a total payment of US$ 13.3 million in case of a successful completion of the project.
Access to articles dating back more than six months is not available free of charge. You can gain access by becoming a paid Focus Taiwan member.
※This website's content, including but not limited to text, images and video, cannot be reproduced, retransmitted or publicly broadcast without the authorization of CNA.